Moreover, considering the CVD continuum where it progresses from risk factors such as diabetes to atherosclerosis and CHD, until it leads to heart failure or death [46], GLP-1 analogues act in different stages of this pathophysiological process (see Fig. 1) without increasing the incidence of arrhythmia or hospitalization or worsening heart failure [22, 40, 47–54]. Here, GCG is linked to diabetes mellitus.